AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of news paper publication of 2nd quarter financial results11-11-2023
11-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audit recording of Earnings Call held on 10th November 2023 on second quarter financial results10-11-2023
Q2FY24 Quarterly Result Announced for Aurobindo Pharma Ltd.
Pharmaceutical company Aurobindo Pharma announced Q2FY24 results: Revenue from operations increased by 25.8% YoY to Rs 7,219 crore with growth seen across key segments US formulations (excluding Puerto Rico) revenue increased by 35.7% YoY to Rs 3,385 crore (USD 409 million) Europe formulation revenue increased by 16.7% YoY to Rs 1,769 crore (EUR 197 million) Growth markets revenue increased by 24.7% YoY to Rs 564 crore (USD 68 million) ARV revenue increased by 52.1% YoY to Rs 250 crore (USD 30 million) API revenue grew by 20.3% YoY to Rs 1,166 crore EBITDA before Forex and Other income stood at Rs 1,403 crore; EBITDA margin of 19.4 % Research & Development (R&D;) spend stood at Rs 300 crore, 4.2% of revenues (vs. Q1 FY24: 5.7%) Received final approval for 15 ANDAs including 3 injectable products from the USFDA Net Profit after Share of Profit/Loss of JV and minority interest at Rs 752 crore, vs. Rs 409 crore in Q2FY23 Basic & Diluted EPS grew by 83.6% YoY to Rs 12.83 per share Board has approved interim dividend at 300% i.e. Rs 3 per equity share of Re 1 for the year FY24 Commenting on the company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said, “This is yet another quarter with highest ever sales, driven by robust performance across the markets, and continued margin expansion, aided by operational leverage and efficiencies. With our strong product pipeline, focus on compliance and key projects in advanced stages, we will continue our growth journey, while generating value for our stakeholders.” Result PDF10-11-2023
AUROBINDO PHARMA LTD. - 524804 - Unaudited Financial Results For The Quarter Ended 30Th September 2023.
Unaudited Financial Results for the quarter ended 30th September 2023.09-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
Earning Presentation on Q2FY24 Unaudited Financial Results09-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on unaudited financial results for the 2nd Quarter ended 30th September 2023.09-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Change in Directorate
Board of Directors appointed Dr. Satakarni Makkapati as Non-executive and Non-independent Director of the Company.09-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Acquisition
Board has approved the acquisition entire equity share capital of Theranym Biologics Private Limited, a 100% stepdown subsidiary, to make it a direct subsidiary.09-11-2023
Aurobindo Pharma Q2 results: Net profit jumps 83% to Rs 752 crore
The company had reported a profit of Rs 409.4 crore in the same period last year09-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Dividend Updates
Board of Directors approved 300% interim dividend (i.e. Rs.3 per share of Re. 1 each) and it will be paid on 4th December 2023.09-11-2023